TY - JOUR
T1 - COVID-19 and metabolic disease
T2 - mechanisms and clinical management
AU - Steenblock, Charlotte
AU - Schwarz, Peter E. H.
AU - Ludwig, Barbara
AU - Linkermann, Andreas
AU - Zimmet, Paul
AU - Kulebyakin, Konstantin
AU - Tkachuk, Vsevolod A.
AU - Markov, Alexander G.
AU - Lehnert, Hendrik
AU - de Angelis, Martin Hrabě
AU - Rietzsch, Hannes
AU - Rodionov, Roman N.
AU - Khunti, Kamlesh
AU - Hopkins, David
AU - Birkenfeld, Andreas L.
AU - Boehm, Bernhard
AU - Holt, Richard I. G.
AU - Skyler, Jay S.
AU - DeVries, J. Hans
AU - Renard, Eric
AU - Eckel, Robert H.
AU - Alberti, K. George M. M.
AU - Geloneze, Bruno
AU - Chan, Juliana C.
AU - Mbanya, Jean Claude
AU - Onyegbutulem, Henry C.
AU - Ramachandran, Ambady
AU - Basit, Abdul
AU - Hassanein, Mohamed
AU - Bewick, Gavin
AU - Spinas, Giatgen A.
AU - Beuschlein, Felix
AU - Landgraf, R. diger
AU - Rubino, Francesco
AU - Mingrone, Geltrude
AU - Bornstein, Stefan R.
N1 - Funding Information: KK reports acting as a consultant or speaker, or receiving grants for investigator-initiated studies for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer Ingelheim, Bayer, Berlin-Chemie AG–Menarini Group, Janssen, and Napp. JSS reports personal fees as a consultant or advisor for Abvance, Adocia, Astra-Zeneca, Avotres, Bayer, Biozeus, Boehringer-Ingelheim, Dalcor, Dance Biopharm–Aerami Therapeutics, Diavacs, Duologics, Elcelyx, Eli Lilly, Enthera, Esperion, Geneuro, Ideal Life, Imcyse, Immunomolecular Therapeutics, Intarcia, Kamada, Kriya, Moerae Matrix, Novo-Nordisk, Oramed, Orgenesis, Pila Pharma, Precigen ActoBiotics, Preziba/Signos, Provention Bio, Sanofi, Tolerion, Valeritas, Viacyte, Viela Bio, vTv Therapeutics, and Zafgen. JHDV reports personal fees as consultant or advisor for Adocia, Novo Nordisk, and Zealand. ER reports personal fees as consultant or advisor for Abbott, Air Liquide, AstraZeneca, Boehringer-Ingelheim, Cellnovo, Dexcom, Eli Lilly, Insulet, Johnson & Johnson (Animas, LifeScan), Medirio, Medtronic, Novo Nordisk, Roche Diagnostics, Sanofi-Aventis, and Tandem; and research grant or material support from Abbott, Dexcom, Insulet, Roche Diagnostics, and Tandem. BG reports personal fees as consultant or advisor for Novo Nordisk, Pfizer, Merck Sharp & Dohme, Astra Zeneca, and Takeda. FR reports personal fees as a consultant or advisor for Ethicon, Medtronic, and Novo Nordisk. All other authors declare no competing interests. Funding Information: The work of CS, AL, BL, and SRB is partly supported by grants from the Deutsche Forschungsgemeinschaft, a German Research foundation (project number 314061271 and 288034826). AL is supported by an additional grant from DFG (project number 324141047). Publisher Copyright: © 2021 Elsevier Ltd
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.
AB - Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.
UR - http://www.scopus.com/inward/record.url?scp=85117325389&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S2213-8587(21)00244-8
DO - https://doi.org/10.1016/S2213-8587(21)00244-8
M3 - Review article
SN - 2213-8587
VL - 9
SP - 786
EP - 798
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 11
ER -